Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evolved to
become the centerpiece of therapy for myelofibrosis (MF), and its use in patients with …

The Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway
is an evolutionarily conserved mechanism of transmembrane signal transduction that …

Ruxolitinib is a Janus kinase (JAK)(JAK1/JAK2) inhibitor that has demonstrated superiority
over placebo and best available therapy (BAT) in the Controlled Myelofibrosis Study with …

Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative
neoplasms with variable risk of evolution into post-PV and post-ET myelofibrosis, from now …

Allogeneic hematopoietic stem cell transplantation is curative in myelofibrosis, and current
prognostic scoring systems aim to select patients for transplantation. Here, we aimed to …

Background The JAK/STAT pathway transduces signals from multiple cytokines and controls
haematopoiesis, immunity and inflammation. In addition, pathological activation is seen in …

Allogeneic hematopoietic stem cell transplantation (SCT) is the only curative option for
patients with primary myelofibrosis (PMF), but information on its net advantage over …

According to the 2008 World Health Organization (WHO) classification, classical
Philadelphia chromosome/BCR-ABL negative chronic myeloproliferative neoplasms (MPNs) …

Ruxolitinib (INCB 018424) is the first JAK 1/JAK 2 inhibitor approved for treatment of
myelofibrosis. JAK/STAT‐signalling is known to be involved in the regulation of CD 4+ T …

Myelofibrosis (MF) is a BCR-ABL1–negative myeloproliferative neoplasm characterized by
clonal myeloproliferation, dysregulated kinase signaling, and release of abnormal cytokines …